Clinical trials investigating MSCs for COPD treatment
| NCT number | Study design | No. | Cell type | Route | FU | Primary outcome | Study completion | Remarks |
| NCT00683722 (USA)81 | Placebo-ctrl Randomised Double-blind | 62 | Allog. BM-MSC | Intravenous | 2 y | Safety/efficacy (phase II) | 2010 December | |
| NCT01306513 (The Netherlands)82 | Single group Open label | 10 | Autol. BM-MSC | Intravenous | 1 y | Safety (phase I) | 2012 November | With LVRS |
| NCT01758055 (Iran)90 | Single group Open label | 12 | Autol. BM-MSC | Endobronchial | n.s. | Safety (phase I) | 2014 January | |
| NCT01872624 (Brazil)83 | Placebo-ctrl Non-randomised Open label | 10 | Allog. BM-MSC | Endobronchial | 4 mo | Safety (phase I) | 2015 March | With EB valves |
| NCT02645305 (Vietnam)90 | Single group Open label | 20 | Autol. AT-MSC | Intravenous | 1 y | Safety/efficacy (phase II) | 2016 December | With APRP |
| NCT02041000 (USA)90 | Single group Open label | 100 | Autol. AT-MSC | Intravenous | 6 mo | Safety/efficacy (phase II) | 2017 January | Commercial (Bioheart) |
| NCT02412332 (Brazil)90 | Placebo-ctrl Randomised Open label | 20 | Autol. AT-MSC, BMMC or both | Intravenous | 1 y | Safety/efficacy (phase II) | 2017 April | |
| NCT01849159 (Russia)90 | Placebo-ctrl Randomised Open label | 30 | Allog. BM-MSC | Intravenous | 2 y | Safety/efficacy (phase II) | 2017 June | Hypoxia-cultured |
| NCT02216630 (USA)90 | Single group Open label | 200 | Autol. AT-MSC | Intravenous | 1 y | Safety/efficacy (phase II) | 2017 August | Commercial (Kimera) |
| NCT02161744 (USA)90 | Single group Open label | 60 | Autol. AT-MSC | Intravenous | 1 y | Safety/efficacy (phase I) | 2017 August | |
| NCT01559051 (USA)90 | Single group Open label | 100 | Autol. AT-MSC | Intravenous/ endobronchial | 6 mo | Safety/efficacy (phase II) | 2017 November | Commercial (Ageless Regenerative Institute) |
| NCT02348060 (USA)90 | Single group Open label | 75 | Autol. AT-MSC | n.s. | 1 y | Quality of life | 2018 February | Commercial (StemGenex) |
Allog., allogeneic; APRP, activated platelet-rich plasma (from peripheral blood); AT-MSC, adipose tissue-derived stem cells; Autol., autologous; BM-MSC, bone marrow-derived mesenchymal stromal cells; BMMCs, bone marrow-derived mononuclear cells; Ctrl, controlled; d, day; FU, follow-up; LVRS, lung volume reduction surgery; mo, month; n.s., not specified; NCT, ClinicalTrials.gov Identifier number; No., number of participants enrolled; route, route of administration; y, year.